ENTERA BIO LTD. Restricted Cash, Current
ENTERA BIO LTD. (ENTX) had Restricted Cash, Current of $7.78 million as of 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:RestrictedCashCurrent · last filed 2026-03-27
- 2025-12-31: Restricted Cash, Current $7.78M.
- 2024-12-31: Restricted Cash, Current $0.00.
| Period end | Restricted Cash, Current |
|---|---|
| 2025-12-31 | $7.78M 10-K · filed 2026-03-27 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |